Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod IncfiledCriticalPfizer Prod Inc
Priority to DO2002000430ApriorityCriticalpatent/DOP2002000430A/en
Publication of DOP2002000430ApublicationCriticalpatent/DOP2002000430A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Esta invención se refiere a derivados de ácido cicioalquilpirrol-3-carboxílico y denvados de ácido heterocicloalquilpirrol-3-carboxílico que se unen con alta selectividad ylo alta afinidad al sitio de la benzodiazepina de los receptores GABAA. Esta invención se refiere también a composiciones farmacéuticas que comprenden tales compuestos y al uso de tales compuestos en el tratamiento de enfermedades del sistema nervioso central (CNS). Esta invención se refiere también al uso de estos denvados de ácido cicloalquilpirrol-3-carboxílico y denvados de ácido heterocicloalquilpirrol10 3-carboxílico en combinación con otros agentes del CNS, uno o vanos, para potenciar los efectos de los otros agentes del CNS. Adicionalmente, esta invención se refiere al uso de tales compuestos como sondas para la detección de los receptores GABAA en secciones de tejidos.This invention relates to cycloalkylpyrrol-3-carboxylic acid derivatives and heterocycloalkylpyrrol-3-carboxylic acid denotes that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of diseases of the central nervous system (CNS). This invention also relates to the use of these cycloalkylpyrrol-3-carboxylic acid denvados and heterocycloalkylpyrrol10 3-carboxylic acid denvates in combination with other CNS agents, one or several, to enhance the effects of the other CNS agents. Additionally, this invention relates to the use of such compounds as probes for the detection of GABAA receptors in tissue sections.
DO2002000430A2002-06-262002-06-26
CICLOALQUILPRIRROL-3-CARBOXILICO ACID DERIVATIVES AND HETEROCICLOALQUILPIRROL-3-CARBOXILICO ACID DERIVATIVES.
DOP2002000430A
(en)
A compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition, methods for altering gabaa receptor signal transduction activity, for the treatment of anxiety, depression, sleep disorder, schizophrenia, hyperactivity disorder, or attention deficit disorder. memory improvement, and to demonstrate the presence of gabaa receptors in a cell or tissue sample, packaged pharmaceutical composition, and, use of a compound or salt
Compounds derived from substituted quinazolinediones, pde7 and pde8 inhibitors; pharmaceutical composition comprising them; procedure for preparing these; and uses in the treatment and / or prevention of inflammatory, immune-inflammatory, gi, bone, cancer, among others.
Compounds derived from pyrazolo [3,4-b] pyridin-5-yl, inhibitors of phosphodiesterase type iv (pde4) and antagonist of muscarinic acetylcholine receptors (machr); pharmaceutical composition comprising them; and its use in the preparation of useful medicines in the treatment of respiratory and allergic diseases